Genialis Debuts ResponderID™ for Clinical Biomarker Discovery
Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, today announced the launch of ResponderID™, a new AI/ML-enabled platform specifically for use in clinical biomarker discovery. ResponderID™ may be implemented to support Pharma drug pipelines and diagnostic test product portfolios from conception to market.
Read the press release in its entirety here.
